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Abstract
This masters’ thesis aims to examine the impact of the legalization of marijuana for recreational
use on the death toll from opioid misuse in the state of Colorado. This investigation was done using the
Synthetic Controls Method via data collected primarily from the CDC and IPUMS databases. The results
indicate that the 2012 legalization policy in Colorado appears to reduce the number of deaths due to opioid
overdoses.
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The Impact of Legalization of Marijuana on Opioid Overdose Deaths
Introduction
Policy Background
One of the many issues at the forefront of the United States’ political landscape presently
is the debate over the legalization of marijuana. Cannabis was classified as a Schedule I drug in
the United States under the Controlled Substances Act of 1970 because it was considered to have
no accepted medical use. In 2009 however, the American Medical Association (AMA) adopted a
stance urging the federal government to review the case for rescheduling marijuana, stating that
doing so would “facilitate research and development of cannabinoid-based medicine” (AMA,
2009). Oregon was the first state in the country to decriminalize marijuana in 1973; but it wasn't
until 1996 that legalization policies were enacted. Between the years 2000 to 2011, twelve states
voted for the legalization of medical marijuana. However, as federal laws still classified marijuana
as illegal, individuals could be indicted for consuming and possessing the drug. In 2012, Colorado
became the first state to legalize recreational marijuana through Amendment 64. Washington state
closely followed it, and since then, eight states as well as the District of Colombia have legalized
it for recreational use (although some states still prohibit sales for recreational purposes). A vast
quantity of literature exists pertaining to the pros and cons of legalizing marijuana usage via
analyses conducted in the fields of criminology, sociology, and economics, among others. Several
studies show that there are marked differences between medical and recreational marijuana strains,
primary of which being that medical marijuana contains a higher Cannabidiol (CBD) content;
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whereas the latter, a higher content of Tetrahydrocannabinol (THC) 1 . Is it to be noted that
investigation has shown that THC content is the factor that seems to provide pain relief. The second
key distinction is that individuals need to have a qualifying condition in order to obtain a medical
marijuana recommendation (to be renewed on a regular basis) by a physician; while on the other
hand, recreational marijuana can be bought by any adult. Given these factors, this paper focuses
on recreational marijuana in order to study the impact of its legalization on the number deaths from
opioid misuse.
Motivation
The latest reports by the Centers for Disease Control (CDC) show a substantial proportion
of the American population overdosing on opioids in recent times; leading to this misuse (of
opioids) being classified as a national crisis. As opioids are drugs that are generally prescribed for
chronic pain, their usage, therefore, cannot be entirely stopped. The US Department of Health and
Human Services (HHS) claims that over a hundred and thirty people a day die from opioid-related
drug overdoses2. The Colorado Consortium for Prescription Drug Abuse Prevention also estimates
that opioid overdoses result in three hundred deaths per year in Colorado3. It has been found that
about twenty-nine percent of patients who were prescribed opioids for chronic pain misuse them
(Vowles et al., 2015); and that about eighty percent of people who use heroin illegally first misused
prescription opioids (Muhuri et al., 2013). A recent paper by Alpert et al., (2018) published in the
American Economic Journal: Economic Policy focuses on the increase in heroin overdoses across
the U.S. The authors believe that, around 2010, there was a sizeable shift from the abuse of

1

See: Atakan Z. (2012), Lafaye, G. et al. (2017), https://www.health.harvard.edu/staying-healthy/medical-marijuanaknow-the-facts
2
https://www.hhs.gov/opioids/
3
http://www.corxconsortium.org/
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prescription opioids to heroin abuse due to the reformulation of the drug OxyContin which made
it harder to crush and dissolve. They also observed that the states that saw a large volume of
existing users switch from the reformulated OxyContin to heroin in the short run, had in fact
previously recorded high rates of OxyContin misuse. The paper concludes that such supply-side
disruptions may lead to an increase in substitutes across opioid-drug types rather than reductions
in overall opioid overdoses. In light of such alarming figures, the National Institutes of Health
(NIH), in order to help solve the opioid crisis and prevent opioid misuse, has deemed necessary
the determination of innovative and healthier strategies to manage chronic pain4. While there are
no marijuana-based products for pain relief approved by the United States Food and Drug
Administration (FDA) currently, informal evidence exists suggesting that marijuana may in fact
help ease certain types of chronic pain; thus making it a good focus for this study.
Evaluation
The analysis in this paper is conducted using the Synthetic Controls Method (SCM), which
is one of the latest popular methods5 used for evaluating public policy. This is because it delivers
a quantifiable backing for specific case-studies by generating a “synthetic control region”. This
hypothetical counterfactual region, generated using statistical software, simulates what the
outcome path of the state would look like if it had not undergone a particular policy intervention;
i.e. the trend that the opioid-related death rates would have followed in Colorado if not for
Amendment 64. This method was carried out by taking the weighted average of pre-legalization
opioid-related death rates from a list of “control” states. The states forming the synthetic control

4
5

https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative
Check: Abadie A. et al. (2010), Billmeier A. & Nannicini T. (2013), Abadie A. & Gardeazabal J. (2003)
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were selected from the U.S. states that had not legalized marijuana for recreational use during the
investigative timeline. The affected state (in this case, Colorado) and its synthetic control
counterpart were then used to study the policy’s effectiveness i.e. how the legalization of marijuana
for recreational use impacts the opioid-related death rate in the state.

Literature Review
There is a strong rhetoric for both the positive and the negative sides of the marijuana legalization
debate. Furthermore, there are a large number of articles that seek to examine the effect of the
legalization policies and their potential association with opioid use. There is no doubt however,
that nearly all of the studies agree on the fact that diminishing the dependence on opioids is an
enormous undertaking, and that this reduction in opioid use must be substituted with alternative
treatments. The prevailing public opinion in favor of legalizing marijuana, in combination with
federal guidelines mandating the limited use of opioids could indeed lead to self as well as
prescribed substitutions of marijuana for opioid use (Choo EK et al., 2016). A study by Hill and
Saxon published in The Journal of the American Medical Association (JAMA) analyzing more
than five years of opioid prescription data discovered that post-legalization, the quantity of
prescriptions decreased substantially; establishing that there was a rampant shift away from opioid
to marijuana consumption (Hill KP & Saxon AJ, 2018). However, this study could not establish if
this move was spearheaded by the patients or by the physicians. There appear to be numerous
studies that center on examining the link between medical marijuana legalization and opioid
overdose deaths; but fewer that focus on recreational marijuana use due to lack of data and
opportunity for research. This has led to emerging concerns that while medical marijuana use may
indeed be a good substitute for prescription opioid use, the use of recreational marijuana may in
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fact be an accelerant for prescription opioid misuse, making it paramount to understand and look
into the impact of recreational marijuana laws on opioid consumption levels. The paper by Yuayn
Shi et al. explores this concern. The authors use state-level quarterly prescription drug utilization
records for Medicaid enrollees with the aid of difference-in-difference models to conclude that
there was no evidence that recreational marijuana legalization increased the number of prescription
opioids; but the policy did reduce the consumption of Schedule III 6 opioids in some states
following the legalization. A related study focusing on recreational marijuana is by Melvin D.
Livingston et al. (2017). The paper makes use of an interrupted time-series design for the time
period 2000 to 2015 in order to compare the changes in monthly opioid-related deaths before and
after the policy. According to the study, after the legalization of marijuana for recreational use in
Colorado, opioid-related deaths decreased by approximately 0.7 deaths per month. However, there
have been no studies so far that have employed the SCM to study the effects of this legalization
policy; and this analysis, precisely, is what this particular paper endeavors to accomplish.

Data & Implementation
Research Design
The investigative timeline was set from 1999 to 2016, on account of available data. This
period of interest for the study ensured that there were seventeen years of data prior to the
enactment of the legalization policy. It would have enhanced this study significantly if a larger
sample of pre-intervention data were available for analysis, thus ensuring a higher degree of
robustness with respect to the results (Abadie et al., 2010). To begin, the appropriate covariates

6

Substances that have less potential for abuse than substances classified as Schedules I or II
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that would possibly have a significant impact on the opioid overdose death rates were identified.
Given the availability of data, the final list of predictors used were per capita income,
unemployment rates, the state’s expenditure on health as a percent of GDP, age distribution of the
population, sex composition of the population, the population’s race make-up, and the educational
levels of the population. There is scope for the addition of more relevant predictor variables such
as state crime rates, industry-composition of the state, and so on which could further enrich the
model. This task, however, was limited due to lack of available data. Next, the donor states that
would help synthesize the control state were established. The synthetic state is constructed as a
weighted average of potential control states, chosen such that the resulting synthetic state best
reproduces the values of the predictors before the legalization of marijuana for recreational use.
Because the synthetic state is meant to reproduce the opioid overdose death rates that would have
been observed for the control state (Colorado) in the absence of this legalization policy, the state
of Washington was excluded from the list of donor due to a similar policy being enacted in the
considered time frame.
Data Sources & Collection
Primarily, the comprehensive mortality information contained in the CDC database for
different opioid classifications was used to collect data on the death rates. CDC data is collected
on natural opioids (morphine and codeine), semi-synthetic opioids (oxycodone, hydrocodone,
hydromorphone, and oxymorphone), synthetic opioids (methadone, tramadol, and fentanyl), as
well as heroin, an illegal opioid synthesized from morphine. Opioid overdose deaths (age-adjusted)
were acquired from the ‘CDC WONDER’ database using the ‘Mortality Files’7 for the time period

7

https://wonder.cdc.gov/mcd.html
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1999 to 2016. Drug overdose deaths were defined according to the 10th revision of the
International Statistical Classification of Diseases i.e. ICD-10 codes (which included the following
categories: X40-X44, X60-X64, and Y10-Y14); in addition to specifically opioids (which included
the following categories: T40.1-T40.4). Data on state unemployment rates and state health
expenditure for the same time period was collected from the Bureau of Labor Statistics (BLS)8.
Additionally, data on states-wise demographics such as age, sex, marital status, per capita income,
and educational level was amassed from the Integrated Public Use Microdata Series (IPUMS)9.

Results
From Figure 1 below, it can be observed that the trend of opioid-related overdose death rates in
Colorado and the rest of the United States appear to progress on a similar path.
And in order to evaluate the effect of the 2012 legalization policy of marijuana for recreational use
on the aforementioned death rates in Colorado, the fundamental question that arises is: How to
determine what path these opioid-related death rates would have followed in Colorado in the
absence of the recreational marijuana legalization policy?

8
9

https://www.bls.gov/data/
https://usa.ipums.org/usa/
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Figure 1

Like discussed above, the synthetic control method provides the best and most systematic way to
estimate this counterfactual. Synthetic Colorado was constructed as a “convex combination” of the
states in the donor pool that most closely resembled Colorado in terms of pre-legalization values
of the relevant predictors. The following table displays the weights of each control state in the
synthetic Colorado. The weights reported in Table 1 indicate that the opioid-related death trends
in Colorado prior to the legalization of marijuana for recreational use is best reproduced by a
combination of the states of Alaska, Arizona, Massachusetts, Nevada, New Hampshire, Utah, and
Virginia. All the other states present in the donor pool were assigned zero weights.
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Table 1: State Weights in the Synthetic Colorado
State

Weight

Alaska

0.097

Arizona

0.003

Massachusetts

0.081

Nevada

0.158

New Hampshire

0.117

Utah

0.173

Virginia

0.371

Total

1

The ensuing results obtained from conducting this analysis are displayed below. Table 2 compares
the pretreatment opioid-related death rates in addition to other characteristics of the actual state of
Colorado with that of the generated synthetic Colorado, as well as with the average of the states in
the donor pool. It can be noted that the SCM does indeed provide a counterfactual that can be
accurately used for comparison with the treated state, Colorado.
On the other hand, the average values of the death rates in the states that did not implement the
legalization policy in the investigative time period of 1999 to 2016 do not seem to provide a
suitable control group for Colorado when compared to those generated by the formation of the
synthetic state. Therefore, it can be said with confidence that synthetic Colorado provides a more
accurate reproduction of the average values of the opioid related death rates that are present in
actual Colorado. Consequently, the SCM can be used to precisely analyze what path the opioidrelated death trends would have taken in Colorado in the absence of the legalization policy of 2012.
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Table1: Predictor Means
Variables

Real Colorado

Synthetic Colorado

Average of Control
States

5.3

5.030723

5.6213501

0.1237172
0.1306196
0.1476538
0.1579112
0.1162098
0.0690676

0.1288234
0.1232939
0.1448169
0.1506744
0.1160114
0.0710131

0.1245
0.115556
0.138258
0.153121
0.122243
0.081441

0.4009644
0.4558596

0.411242
0.447872

0.398184
0.44894

0.114054
0.0300854
0.8612794

0.0507353
0.0788065
0.8058996

0.052813
0.091314
0.809114

0.4409718
0.2537287

0.389926
0.2805422

0.363798
0.308211

0.5079817

0.5093697

0.615339

Ln(Per Capita Income)

14.51673

14.53484

14.4823

Health Expenditure as a
percentage of GDP

0.1080769

0.1071338

0.1391821

Lagged Death Rate (2011)

23.3921

22.95417

21.527614

Lagged Death Rate (2006)

19.3347

19.64065

18.017618

Lagged Death Rate (2000)

11.7631

11.86461

9.6371611

Unemployment Rate
Percent of Population Aged:
15 to 24
25 to 34
35 to 44
45 to 54
55 to 64
65 to 74
Percent of Population that is:
Unmarried
Married
Percent of Population that is:
Hispanic
Black
White
Percent of population that
completed:
College
High School
Percent of Population that is
Female

This table emphasizes an important feature of synthetic control, namely, the ability to safeguard
against estimation of “extreme counterfactuals that fall far outside the convex hull of the data”
(King and Zheng 2006). The pre-intervention root mean squared prediction error for Colorado was
found to be 0.7671137 (which is universally accepted as fairly small); indicating that the SCM is
able to provide a good fit for the data at hand.
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Accordingly, Figure 2 displays the trend of opioid-related death rates for Colorado and its synthetic
counterpart during the time period 1999 to 2016. It can be seen that synthetic Colorado closely
tracks the path of the opioid-related death rates variable in Colorado for the pre-legalization period
suggesting that the synthetic Colorado could indeed provide a reasonable approximation to the
number of opioid-related deaths from 2012 onwards in Colorado in the absence of the legalization
policy. The two lines begin to diverge noticeably after the legalization went into effect and the real
Colorado line seem to show a lower rate of increase when compared to the trajectory of the
synthetic Colorado. The discrepancy between the two lines insinuates a negative effect of the
legalization of marijuana for recreational use on the number of opioid-related deaths.

Figure 2
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Furthermore, from Figure 3, it can be inferred that the legalization policy did indeed have a large
negative effect on the number of opioid-related death rates. It can be observed that for the post
2012 timeframe, i.e., after the recreational legalization policy was enacted, the death rates due to
opioid overdoses fell to almost 14 per 100,000 deaths.

Figure 3

In order to evaluate the significance of the estimates, it is important to check the robustness of the
results obtained and rule out the possibility that the resultant outcomes could be driven entirely by
chance. Running placebo tests provided one way to answer appropriately the question of chance.
The placebo test was run by first applying the SCM to the donor states i.e. those states that did not
enact the policy of legalization of marijuana for recreational use during the sample period i.e. 1999
to 2012. If the placebo tests showed that the gap estimated for Colorado is large relative to the gaps
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for the states that did not implement any legalization of recreational marijuana policy, then it could
be concluded that the analysis provides significant evidence of a negative effect of the 2012
legalization policy on the deaths due to opioid overdose in the state of Colorado (Abadie et al.,
2010). The series of placebo studies was constructed by iteratively applying the SCM used to
estimate the effect of the 2012 legalization policy in Colorado to every other state in the donor
pool. In each iteration, data was reassigned in order to enable investigation as if one of the states
in the donor pool would have passed the 2012 legalization policy instead of Colorado. The
estimated effect was then computed with each placebo run providing a distribution of estimated
gaps for the states where no intervention took place. Figure 4 below displays the results for the
placebo test.

Figure 4
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The light-colored lines represent the gap associated with each of the donor state runs of the test
and show the difference in death rates between the respective state and its respective synthetic
version. As the figure makes apparent, the estimated gap for Colorado after 2012 is large relative
to the distribution of the gaps for the states in the donor pool.

Discussion
This report trails the procedure of the SCM described through the paper by Abadie, Diamond, and
Hainmueller. As their paper acknowledges, “comparative case study research has broad potential
in the social science but its empirical implementation of is plagued by inferential challenges and
ambiguity about the choice of valid control groups” (Abadie, A et al., 2010). Hence, using the
SCM as a data-driven procedure to select the appropriate comparison units provided a suitable
method to analyze the impact of the legalization of marijuana on deaths due to opioid overuse.
Using the SCM to analyze the effect of the legalization policy at a county-level analysis rather
than a state-level analysis may prove to be a more forceful study. This task, however, was outside
the scope of this study. Nevertheless, this report does strongly indicate that the legalization of
recreational marijuana would result in a decrease in the number of deaths due to opioid misuse.
Due to the liberal prescribing of opioid drugs during the 1990s, dependency on and the abuse of
opioids seems to have grown exponentially in the United States; making the country one of the
leading consumer of opioids10 (UNODC World Drug Report 2018). Thus, there has been a rise in
resources and programs being directed toward finding substitutes for chronic-pain treatments that
could help bring a reprieve to the opioid crisis. Due to emerging research on its medical benefits,

10

https://www.unodc.org/wdr2018/prelaunch/WDR18_Booklet_2_GLOBAL.pdf
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marijuana offers to be a good substitute to look into. It has so far, however, proven difficult to
study the health impacts of recreational marijuana due to its illegality; causing a hinderance to data
collection. There has been an ever-increasing public support for marijuana law reform in the recent
years, as well as encouragement from non-profit organizations such as The Drug Policy Alliance
(DPA)11 to regulate marijuana similar to alcohol and tobacco. There is general consensus that
allowing the possession, use and sales of marijuana could in fact increase tax revenue, generate
commerce and support the agricultural economy. Hence, taking into account all the
aforementioned factors, it deems a vital mission to understand the health impacts of marijuana. As
there still exist a lot of unknown aspects regarding how the recreational legalization policy could
affect marijuana being used as a substitute for opioids, in the treatment of chronic pain, research
on it, as carried out by this paper, seems to hold pronounced importance in the present-day.

11

http://www.drugpolicy.org/
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